Press Releases July 28, 2026 04:05 PM

Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

Ceribell to present at Canaccord Genuity Annual Growth Conference to discuss neurological diagnostic advancements

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
CBLL

CeriBell, a medical technology firm specializing in rapid neurological diagnostics, announced its CFO will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The company highlights its innovative EEG system that aids acute neurological patient care using AI-powered technology, with FDA clearance for use in U.S. emergency and intensive care settings.

Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
CBLL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CFO Scott Blumberg will speak at the Canaccord Genuity Growth Conference on August 12, 2026.
  • Ceribell's novel Ceribell System uses portable EEG technology with AI algorithms to improve rapid diagnosis in acute neurological care.
  • The system is FDA-cleared for detecting seizures and delirium in intensive care units and emergency rooms across the U.S.
  • Impacted sectors include healthcare technology, medical devices, neurology services, and AI in medical diagnostics.

SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston. The fireside chat will take place on Wednesday, August 12, 2026, at 6:00 a.m. Pacific Daylight Time / 9:00 a.m. Eastern Daylight Time.

Event: Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026
Time: 6:00 a.m. PDT / 9:00 a.m. EDT

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. 

About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston
Gilmartin Group
[email protected] 

Media Contact
Brian Price
[email protected]


Risks

  • No new product or financial updates were disclosed, limiting immediate growth visibility.
  • Market adoption of new medical technologies can be slow due to regulatory, clinical, and hospital procurement processes.
  • Clinical effectiveness and competitive advancements in neurological monitoring could impact future company performance.

More from Press Releases

NOV Reports Second Quarter 2026 Earnings Jul 28, 2026 Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting Jul 28, 2026 Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026 Jul 28, 2026 Kentucky First Federal Bancorp Board of Directors Announces Declaration of $0.05 Quarterly Dividend Jul 28, 2026 Sound Financial Bancorp, Inc. Q2 2026 Results Jul 28, 2026